Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory illness with various endotypes in eastern and western patients. Targeted biologics are presently utilised to treat CRSwNP, however the results vary greatly. This review focuses on the current usage of biologics in the treatment of CRSwNP. Monoclonal biologics have been employed as a novel therapy for a variety of allergy illnesses and allergic disorders. Numerous biomarkers have been examined and found to be closely connected with CRSwNP during the past several decades, boosting understanding of inflammatory patterns and endotype classifications for CRSwNP and generating discussion on the use of biologics in CRSwNP. Efficacy findings from various study groups vary, but it has been discovered that individuals with TH-2-driven inflammatory patterns respond better to biologics than those with non-TH-2-driven CRSwNP. These findings highlight the significance and urgency of creating biologics criteria in CRSwNP.
Precise determination of patient criteria, identification of biomarkers for therapy based on CRSwNP endotyping and determination of long-term usage contraindications can help to optimise treatment strategies and improve therapeutic effectiveness of biologics to achieve long-term management from early stage onwards.
